Cargando…
Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists
[Image: see text] We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB(1) receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPγS binding assay, and in a competition association...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734604/ https://www.ncbi.nlm.nih.gov/pubmed/29111736 http://dx.doi.org/10.1021/acs.jmedchem.7b00861 |
_version_ | 1783287080599683072 |
---|---|
author | Xia, Lizi de Vries, Henk Lenselink, Eelke B. Louvel, Julien Waring, Michael J. Cheng, Leifeng Pahlén, Sara Petersson, Maria J. Schell, Peter Olsson, Roine I. Heitman, Laura H. Sheppard, Robert J. IJzerman, Adriaan P. |
author_facet | Xia, Lizi de Vries, Henk Lenselink, Eelke B. Louvel, Julien Waring, Michael J. Cheng, Leifeng Pahlén, Sara Petersson, Maria J. Schell, Peter Olsson, Roine I. Heitman, Laura H. Sheppard, Robert J. IJzerman, Adriaan P. |
author_sort | Xia, Lizi |
collection | PubMed |
description | [Image: see text] We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB(1) receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPγS binding assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The compounds show high affinities and a diverse range of kinetic profiles at the CB(1) receptor and their structure–kinetic relationships (SKRs) were established. Using the recently resolved hCB(1) receptor crystal structures, we also performed a modeling study that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB(1) receptor antagonists in the early phases of drug discovery. |
format | Online Article Text |
id | pubmed-5734604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-57346042017-12-19 Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists Xia, Lizi de Vries, Henk Lenselink, Eelke B. Louvel, Julien Waring, Michael J. Cheng, Leifeng Pahlén, Sara Petersson, Maria J. Schell, Peter Olsson, Roine I. Heitman, Laura H. Sheppard, Robert J. IJzerman, Adriaan P. J Med Chem [Image: see text] We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB(1) receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPγS binding assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The compounds show high affinities and a diverse range of kinetic profiles at the CB(1) receptor and their structure–kinetic relationships (SKRs) were established. Using the recently resolved hCB(1) receptor crystal structures, we also performed a modeling study that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB(1) receptor antagonists in the early phases of drug discovery. American Chemical Society 2017-11-07 2017-12-14 /pmc/articles/PMC5734604/ /pubmed/29111736 http://dx.doi.org/10.1021/acs.jmedchem.7b00861 Text en Copyright © 2017 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes. |
spellingShingle | Xia, Lizi de Vries, Henk Lenselink, Eelke B. Louvel, Julien Waring, Michael J. Cheng, Leifeng Pahlén, Sara Petersson, Maria J. Schell, Peter Olsson, Roine I. Heitman, Laura H. Sheppard, Robert J. IJzerman, Adriaan P. Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists |
title | Structure–Affinity
Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide
Derivatives as Human Cannabinoid 1 Receptor Antagonists |
title_full | Structure–Affinity
Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide
Derivatives as Human Cannabinoid 1 Receptor Antagonists |
title_fullStr | Structure–Affinity
Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide
Derivatives as Human Cannabinoid 1 Receptor Antagonists |
title_full_unstemmed | Structure–Affinity
Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide
Derivatives as Human Cannabinoid 1 Receptor Antagonists |
title_short | Structure–Affinity
Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide
Derivatives as Human Cannabinoid 1 Receptor Antagonists |
title_sort | structure–affinity
relationships and structure–kinetic relationships of 1,2-diarylimidazol-4-carboxamide
derivatives as human cannabinoid 1 receptor antagonists |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734604/ https://www.ncbi.nlm.nih.gov/pubmed/29111736 http://dx.doi.org/10.1021/acs.jmedchem.7b00861 |
work_keys_str_mv | AT xializi structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT devrieshenk structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT lenselinkeelkeb structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT louveljulien structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT waringmichaelj structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT chengleifeng structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT pahlensara structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT peterssonmariaj structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT schellpeter structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT olssonroinei structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT heitmanlaurah structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT sheppardrobertj structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists AT ijzermanadriaanp structureaffinityrelationshipsandstructurekineticrelationshipsof12diarylimidazol4carboxamidederivativesashumancannabinoid1receptorantagonists |